SANGAMO Regulatory Wednesday, July 1, 2026 0.00 Neutral

Sangamo Therapeutics confirms Ernst & Young LLP consent

Ernst & Young LLP signed off on the content of the company's July 1, 2026 8-K filing. The filing ensures regulatory compliance and third-party sign-off on financial disclosures.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day